Drug intelligence / Profile preview

Iobenguane I-123

Development stage
Approved
Lead developer
GE Healthcare
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Iobenguane I-123 is a radiopharmaceutical diagnostic agent used primarily for imaging of neuroendocrine tumors and disorders of the adrenal medulla. It is a radioactive analog of norepinephrine (noradrenaline) that is selectively taken up by adrenergic nerve terminals via the noradrenaline uptake transporter. Once inside these cells, it accumulates in chromaffin granules and can be visualized using gamma-scintigraphic imaging due to its radioactive iodine isotope (I-123). The main clinical indications include detection and localization of primary or metastatic pheochromocytoma and neuroblastoma, as well as assessment of myocardial sympathetic innervation in certain heart failure patients. It may also be used for evaluation of paragangliomas, carcinoid tumors, adrenal medullary hyperplasia (including MEN syndromes), and medullary thyroid carcinoma. **Developer:** GE Healthcare

Brand names
AdreView
Other names
iobenguane sulfate i-123meta-iodobenzylguanidine I 123
02

Targets

OCT3 (Organic cation transporter 3)MATE2-K (Multidrug and toxin extrusion protein 2)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Iobenguane I-123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iobenguane I-123.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call